Cocrystal Pharma, Inc. Logo

Cocrystal Pharma, Inc.

Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.

COCP | US

Overview

Corporate Details

ISIN(s):
US19188J4094
LEI:
Country:
United States of America
Address:
19805 N. CREEK PARKWAY, 98011 BOTHELL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. The company utilizes its proprietary structure-based drug design technologies and Nobel Prize-winning expertise to create antiviral drugs that target the viral replication process. Its development pipeline includes candidates for the treatment of influenza, coronaviruses (including SARS-CoV-2), norovirus, and hepatitis C. Key programs in its portfolio are at various stages of clinical development, including a Phase 2 trial for an influenza A inhibitor (CC-42344) and a Phase 1 trial for a pan-viral protease inhibitor (CDI-988) targeting norovirus and coronaviruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cocrystal Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cocrystal Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cocrystal Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD
REVVITY, INC. Logo
Provides life sciences & diagnostics technologies to support workflows from discovery to cure.
United States of America
RVTY
REYON PHARMACEUTICAL CO., LTD Logo
Develops & makes APIs, generics, cell/gene therapies, and offers biopharma CDMO services.
South Korea
102460
Rezolute, Inc. Logo
Developing therapies for rare metabolic diseases, focusing on hyperinsulinism-caused hypoglycemia.
United States of America
RZLT
RHYTHM PHARMACEUTICALS, INC. Logo
Develops precision medicines for rare genetic diseases causing severe obesity and hyperphagia.
United States of America
RYTM
RIGEL PHARMACEUTICALS INC Logo
Develops and commercializes small-molecule drugs for hematology, cancer, and autoimmune diseases.
United States of America
RIGL

Talk to a Data Expert

Have a question? We'll get back to you promptly.